Imatinib
Back to searchMolecule Structure
Scientific Name
Imatinib
Description of the Drug
Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00619
http://www.drugbank.ca/drugs/DB00619
Brand Name(s)
Not Available
Company Owner(s)
Mylan Pharmaceuticals Inc, Hikma Pharmaceuticals Usa Inc, Teva Pharmaceuticals Usa, Natco Pharma Ltd, Novartis Pharmaceuticals Corp, Dr Reddys Laboratories Ltd, Apotex Inc, Amneal Pharmaceuticals Of New York Llc, Wockhardt Bio Ag, Sun Pharmaceutical Industries Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
| Platelet-derived growth factor receptor beta | SINGLE PROTEIN | INHIBITOR | CHEMBL1913 |
| Tyrosine-protein kinase ABL | SINGLE PROTEIN | INHIBITOR | CHEMBL1862 |
| Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
Clinical Trial(s)
Unichem Links
| Atlas | imatinib | |||
| SureChEMBL | SCHEMBL3827 | |||
| PharmGKB | PA10804 | |||
| Human Metabolome Database | HMDB0014757 | |||
| WDI | DR9601648 | DR9712313 | ||
| DrugBank | DB00619 | |||
| PubChem: Thomson Pharma | 14859628 | |||
| PubChem | 5291 | |||
| Mcule | MCULE-2384256888 | |||
| LINCS | LSM-1023 | |||
| Nikkaji | J1.337.143A | |||
| PDBe | STI | |||
| NCC | 5101 | |||
| BindingDB | 13530 | |||
| EPA CompTox Dashboard | DTXSID3037125 | |||
| DrugCentral | 1423 | |||
| Brenda | 229530 | 2314 | 229529 | 163324 |
| ChemicalBook | CB7370890 | |||
| Guide to Pharmacology | 5687 | |||
| GSRS | 9fdb59f1-dd06-450e-b973-014d7d4bb468 | |||
| rxnorm | IMATINIB | GLEEVEC | IMATINIB MESYLATE | |
| ChEBI | 45783 | |||
| ZINC | ZINC000019632618 |
